Equillium Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
EQ$1.46-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, · Year EndedDecember 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Operating activities: | ||||
| Net loss | $(13,335) | $(62,428) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Acquired in-process research and development | - | 23,049 | ||
| Depreciation | 126 | 118 | ||
| Stock-based compensation | 3,997 | 4,841 | ||
| Net unrealized loss on foreign currency transactions | 58 | 260 | ||
| Amortization of term loan discount and issuance costs | 180 | 203 | ||
| Amortization of premium and accretion of discounts on investments | (914) | 127 | ||
| Deferred revenue | (9,349) | 25,078 | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (897) | (2,838) | ||
| Prepaid expenses and other current assets | (1,805) | (158) | ||
| Accounts payable | 723 | 2,508 | ||
| Accrued expenses | (554) | 432 | ||
| Right-of-use assets and lease liabilities, net | (13) | 75 | ||
| Net cash used in operating activities | (21,783) | (8,733) | ||
| Investing activities: | ||||
| Purchases of property and equipment | (50) | (279) | ||
| Purchases of short-term investments | (54,712) | (14,962) | ||
| Maturities of short-term investments | 50,000 | 33,225 | ||
| Cash acquired in Bioniz acquisition | - | 700 | ||
| Net cash (used in) provided by investing activities | (4,762) | 18,684 | ||
| Financing activities: | ||||
| Repayment of notes payable | (9,133) | (1,429) | ||
| Common stock repurchased | (260) | - | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 165 | 214 | ||
| Net cash used in financing activities | (9,228) | (1,215) | ||
| Effect of exchange rate changes on cash and cash equivalents | (118) | 5 | ||
| Net (decrease) increase in cash and cash equivalents | (35,891) | 8,741 | ||
| Cash and cash equivalents at beginning of period | 59,107 | 50,366 | ||
| Cash and cash equivalents at end of period | $23,216 | $59,107 | ||
| Supplemental cash flow information: | ||||
| Cash paid for interest | $946 | $847 | ||
| Cash paid for income taxes | $580 | $ | - | |
| Fair value of Bioniz assets acquired | $ | - | $23,049 | |
| Issuance of common stock for Bioniz acquisition | - | (22,542) | ||
| Bioniz net liabilities assumed | $ | - | $507 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.